4Bonaf~ M, Storci G, Franceschi C. Inflamm-aging of the stem cell niehe:breast cancer as a paradigmatie example: breakdown of the multi-shell eytokine network fuels cancer in aged people[ J]. Bioes-says,2012,34( 1 ) :40 -49.
5Navarro G, Sawant RR, Biswas S, et al. P - glycoprotein silencing with siRNA delivered by DOPE - modified PEI overcomes doxorubi- cin resistance in breast cancer ceils [ J ]. Nanomedicine - (Lond) , 2012,7(1) :65 -78.
6Tros - de - Ilarduya C. Serum-resistant lipoplexes in the presence of asialofetuin [ J ]. Methods Mol Biol, 2010,605:425 - 434.
8Howard McNatt M ,Schroll RW, Hurt G J, et al. Contralateral prophy- lactic mastectomy in breast cancer patients who test negative for BRCA mutations[ J ]. Am J Surg,2011,202 (3) :298 - 302.
9Kontos M, Mien DS, Agbaje OF, et al. Factors influencing |oco-re- gional relapse in older breast cancer patients treated with tumor resec- tion and tamoxifen [ J ]. Eur J Surg Oncol, 2011,37 ( 12 ) : 1051 - 1058.
10Lee DS,Kim SH,Suh YJ,et al. Clinical implication of p53 over ex- pression in breast cancer patients younger than 50 years with a tri- ple-negative subtype who undergo a modified radical mastectomy [J]. JpnJClin 0ncol,2011,41(7):854-866.
